Brief: Applied Molecular Transport Presents Additional Data From Oral Amt-101 Phase 2 Fillmore Trial In Chronic Pouchitis
03/03/2023 13:05
March 3 (Reuters) - Applied Molecular Transport Inc
AMTI.O :
* APPLIED MOLECULAR TRANSPORT PRESENTS ADDITIONAL DATA FROM
ORAL
AMT-101 PHASE 2 FILLMORE TRIAL IN CHRONIC POUCHITIS AT ECCO ’23
CONGRESS
* NEW DATA SHOW ORAL AMT-101'S GUT-RESTRICTED PROFILE WITH
TISSUE-LEVEL PHARMACODYNAMICS EFFECTS & NO SYSTEMIC EXPOSURE BY
DESIGN
* TRANSLATIONAL ANALYSIS REVEALS IL-10 BIOLOGICAL RESPONSES
IN
BOTH 3MG AND 10MG DOSE ARMS
Source text for Eikon: ID:nGNXbSDMCW
Further company coverage: AMTI.O
Recent news on Applied Molecular Transport.
See all newsApplied Molecular Transport Inc. expected to post a loss of 50 cents a share - Earnings Preview
Brief: Applied Molecular Transport Inc. - On Oct 23 Got Written Notice Nasdaq Had Granted Co's Request For Continued Listing On Nasdaq
U.S. STOCKS ON THE MOVE-Boston Scientific, Rockwell Medical, Visa
U.S. STOCKS ON THE MOVE-Fox Corp, Cisco Systems, Darden Restaurants
Applied Molecular rises on merger deal with Cyclo Therapeutics